Hepatocellular Carcinoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Hepatocellular Carcinoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 4 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCNCT05557838≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1 | Phase 3 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-06-26 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerNCT05775159Objective response rate (ORR) | Phase 2 | Active, not recruiting | 2026-10-27 | in 68 d | 2026-07-02 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)NCT05822752Best Overall Response (BOR) per Investigator | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2025-08-14 |
| AZN | AstraZeneca | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaNCT07081633Progression free survival (PFS) per RECIST 1.1 | Phase 2 | Active, not recruiting | 2026-11-30 | in 102 d | 2026-05-12 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TVRD | Tvardi Therapeutics, Incorporated | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaNCT05440708Incidence of Adverse Events (AE) | Phase 1/2 | Recruiting | 2027-02-01 | in 165 d | 2026-04-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Hepatocellular Carcinoma
most recently updated first194 studies match. Showing the first 100 of 194 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaNCT060848841. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase | Phase 1/2 | Active, not recruiting | Biological: AZD5851 | Hepatocellular Carcinoma | 94 | 2023-12-14 | 2027-12-13 | in 480 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)NCT07291076Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: Pumitamig, Ipilimumab | Hepatocellular Carcinoma (HCC) | 198 | 2026-03-16 | 2029-10-15 | in 1,152 d | 2026-08-18 |
| EXEL | Exelixis | $13.2B | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Enrolling by invitation | Drug: Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer | 5,000 | 2026-07-30 | 2030-05-31 | in 1,380 d | 2026-08-18 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)NCT06487559Percentage of Participants With Adverse Events (AE) | Phase 1 | Active, not recruiting | Drug: Livmoniplimab, Budigalimab | Hepatocellular Carcinoma (HCC) | 3 | 2024-09-11 | Feb 2027 | ≤ 192 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.NCT07227012Number of Participants With Adverse Events | Phase 1/2 | Recruiting | Biological: PF-08634404, Ipilimumab | Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 138 | 2025-12-01 | 2027-10-18 | in 424 d | 2026-08-17 |
| AZN | AstraZeneca | — | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentNCT03847428Recurrence-free survival (RFS) for Arm A vs Arm C | Phase 3 | Active, not recruiting | Drug: Durvalumab, Bevacizumab · Other: Placebo | Hepatocellular Carcinoma | 908 | 2019-04-29 | 2026-05-15actual | — | 2026-08-14 |
| AZN | AstraZeneca | — | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid TumoursNCT06795022The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy | Hepatocellular Carcinoma | 304 | 2025-03-27 | 2027-06-30 | in 314 d | 2026-08-13 |
| BSX | Boston Scientific Corporation | $73.1B | MANDARIN (S6371)NCT05016245Time to progression (TTP) | Phase 3 | Completed | Combination product: TheraSphere™ Yttrium-90 Glass Microspheres · Procedure: conventional Transarterial Chemoembolization(cTACE) | Inoperable Hepatocellular Carcinoma | 92 | 2021-09-13 | 2026-02-13actual | — | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-400, Itraconazole (ITZ), Bevacizumab | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | 302 | 2023-11-09 | Sep 2027 | ≤ 406 d | 2026-08-04 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationNCT03383458Recurrence-free Survival (RFS) | Phase 3 | Active, not recruiting | Biological: Nivolumab · Other: Placebo | Hepatocellular Carcinoma, Liver Cancer | 545 | 2018-04-18 | 2026-05-27actual | — | 2026-07-31 |
| BSX | Boston Scientific Corporation | $73.1B | TheraSphere With Durvalumab and Tremelimumab for HCCNCT05063565Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | Device: TheraSphere Y-90 glass microsphere therapy · Drug: Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy | Hepatocellular Carcinoma | 100 | 2023-11-03 | Jun 2027 | ≤ 314 d | 2026-07-31 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 Study of the Safety and Tolerability of CTX-10726NCT07419841Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses | Phase 1 | Recruiting | Drug: CTX-10726 | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | 2026-05-28 | 2028-04-01 | in 590 d | 2026-07-31 |
| BSX | Boston Scientific Corporation | $73.1B | A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.NCT07669727observationalPrimary Safety Endpoint | — | Not yet recruiting | Device: TheraSphere | Hepatocellular Carcinoma (HCC) | 140 | Aug 2026 | May 2028 | ≤ 650 d | 2026-07-31 |
| ONC | BeOne Medicines | $545.6B | A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsNCT06427941Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: BGB-B2033, Tislelizumab, Bevacizumab | Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer | 392 | 2024-07-23 | 2028-05-30 | in 649 d | 2026-07-29 |
| TYRA | Tyra Biosciences, Inc | $1.6B | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsNCT06915753Maximum tolerated dose (MTD) | Phase 1 | Recruiting | Drug: TYRA-430 | Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma | 100 | 2025-04-24 | Jan 2028 | ≤ 529 d | 2026-07-29 |
| AZN | AstraZeneca | — | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaNCT03298451results2023-06-18Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg | Phase 3 | Active, not recruiting | Drug: Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2) | Hepatocellular Carcinoma | 1,324 | 2017-10-11 | 2021-08-27actual | — | 2026-07-27 |
| AZN | AstraZeneca | — | MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.NCT07607769observationalTime To Decompensation (TTDec) | — | Recruiting | Drug: STRIDE | Hepatocellular Carcinoma | 200 | 2026-04-16 | 2028-10-31 | in 803 d | 2026-07-27 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| AZN | AstraZeneca | — | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaNCT03778957Progression Free Survival (PFS) for Arm B vs Arm C | Phase 3 | Active, not recruiting | Drug: Durvalumab, Bevacizumab · Other: Placebo · Procedure: Transarterial Chemoembolization (TACE) | Hepatocellular Carcinoma | 724 | 2018-11-30 | 2023-09-11actual | — | 2026-07-15 |
| CHRS | Coherus Oncology, Inc. | $207M | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsNCT04374877[Part A] Dose Limiting Toxicity (DLT) | Phase 1 | Completed | Drug: CHS-388, Pembrolizumab, Toripalimab | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 145 | 2020-04-22 | 2025-05-28actual | — | 2026-07-15 |
| CHRS | Coherus Oncology, Inc. | $207M | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Active, not recruiting | Drug: Casdozokitug, Toripalimab, Bevacizumab | Hepatocellular Carcinoma | 72 | 2024-12-20 | Sep 2027 | ≤ 406 d | 2026-07-15 |
| AZN | AstraZeneca | — | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaNCT06921785To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC | Phase 3 | Recruiting | Drug: Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab | Hepatocellular Carcinoma | 1,220 | 2025-05-06 | 2029-03-16 | in 939 d | 2026-07-14 |
| AZN | AstraZeneca | — | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCNCT05301842Progression Free Survival (PFS) for Arm A vs Arm C | Phase 3 | Active, not recruiting | Drug: Tremelimumab, Durvalumab, Lenvatinib · Procedure: Transarterial Chemoembolization (TACE) | Hepatocellular Carcinoma | 760 | 2022-03-28 | 2026-02-23actual | — | 2026-07-13 |
| AZN | AstraZeneca | — | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerNCT05775159Objective response rate (ORR) | Phase 2 | Active, not recruiting | Drug: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin | Hepatocellular Carcinoma, Biliary Tract Cancer | 294 | 2023-04-24 | 2026-10-27 | in 68 d | 2026-07-02 |
| BMY | Bristol-Myers Squibb | $134.9B | First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)NCT07679061observationalNumber of participants with grade ≥3 immune-mediated liver injury (IMLI) | — | Recruiting | Combination product: Nivolumab plus ipilimumab | Unresectable Hepatocellular Carcinoma | 200 | 2026-03-05 | 2028-02-29 | in 558 d | 2026-07-01 |
| AZN | AstraZeneca | — | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARENCT06040099Progression Free Survival (PFS) | Phase 2 | Active, not recruiting | Drug: Durvalumab, Bevacizumab · Procedure: Transarterial Radioembolization (TARE) | Hepatocellular Carcinoma (HCC) | 58 | 2024-02-13 | 2026-07-01 | — | 2026-06-30 |
| CHRS | Coherus Oncology, Inc. | $207M | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861Nature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higher | Phase 2 | Completed | Drug: SRF388, Atezolizumab, Bevacizumab, Placebo | Hepatocellular Carcinoma | 30 | 2022-04-12 | 2025-06-30actual | — | 2026-06-29 |
| AZN | AstraZeneca | — | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCNCT05557838≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1 | Phase 3 | Active, not recruiting | Drug: Durvalumab, Tremelimumab | Hepatocellular Carcinoma | 214 | 2023-02-15 | 2026-09-30 | in 41 d | 2026-06-26 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaNCT06600321Frequency of Adverse Events (AEs) | Phase 1 | Recruiting | Drug: ALN-BCAT, Pembrolizumab | Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 158 | 2024-12-30 | 2027-09-30 | in 406 d | 2026-06-17 |
| AZN | AstraZeneca | — | CHARM Hepatocellular Carcinoma MEA StudyNCT07650773observationalPatient Clinical Characteristics | — | Not yet recruiting | — | HepatoCellular Carcinoma | 4,000 | 2026-06-30 | 2027-11-30 | in 467 d | 2026-06-16 |
| AZN | AstraZeneca | — | Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyNCT05667064observationalIncidence of ADRs | — | Completed | — | Unresectable Hepatocellular Carcinoma | 1,200 | 2023-05-09 | 2025-07-21actual | — | 2026-06-01 |
| AGEN | Agenus Inc. | $339M | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalNCT06751524expanded access | — | Available | Drug: Botensilimab, Balstililmab | Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), Melanoma, Sarcoma, Ovarian Cancer, Prostate Cancer | — | — | — | — | 2026-05-15 |
| AZN | AstraZeneca | — | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaNCT07081633Progression free survival (PFS) per RECIST 1.1 | Phase 2 | Active, not recruiting | Drug: Durvalumab, Tremelimumab · Combination product: Lenvatinib | Hepatocellular Carcinoma | 114 | 2025-08-05 | 2026-11-30 | in 102 d | 2026-05-12 |
| AZN | AstraZeneca | — | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)NCT05883644Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs) | Phase 3 | Active, not recruiting | Drug: Durvalumab, Tremelimumab | Advanced Hepatocellular Carcinoma | 111 | 2023-06-27 | 2026-03-30actual | — | 2026-04-30 |
| TVRD | Tvardi Therapeutics, Incorporated | $25M | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaNCT05440708Incidence of Adverse Events (AE) | Phase 1/2 | Recruiting | Drug: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab | Hepatocellular Carcinoma | 193 | 2023-03-23 | 2027-02-01 | in 165 d | 2026-04-27 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsNCT03916627Major pathologic response (MPR) at time of surgery for the NSCLC cohorts | Phase 2 | Active, not recruiting | Drug: cemiplimab, Platinum Doublet, fianlimab | Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma | 65 | 2019-07-23 | 2025-03-31actual | — | 2026-04-06 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaNCT04039607Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Nivolumab, Ipilimumab, Sorafenib, lenvatinib | Hepatocellular Carcinoma | 732 | 2019-09-30 | 2026-07-09 | — | 2026-04-06 |
| REPL | Replimune, Inc. | $1.5B | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598Overall Response Rate per modified RECIST 1.1 | Phase 2 | Recruiting | Biological: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy | Hepatocellular Carcinoma, Biliary Tract Cancer | 60 | 2024-08-01 | 2027-12-01 | in 468 d | 2026-04-02 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)NCT06858813Number of Participants with Adverse Events (AE)s | Phase 1 | Recruiting | Drug: Lenvatinib, ABBV-324 | Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer | 232 | 2025-04-14 | Sep 2030 | ≤ 1,502 d | 2026-03-25 |
| 4523.T | Eisai Inc. | $8.7B | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorNCT04008797Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs) | Phase 1/2 | Active, not recruiting | Drug: E7386, Lenvatinib, Doxorubicin, Paclitaxel | Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms | 301 | 2019-07-11 | 2027-03-31 | in 223 d | 2026-03-24 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerNCT05337137Incidence of dose-limiting toxicities (DLTs) | Phase 1/2 | Completed | Drug: Relatlimab, Nivolumab, Bevacizumab · Other: Placebo | Carcinoma, Hepatocellular | 83 | 2022-05-05 | 2025-07-05actual | — | 2026-01-12 |
| REPL | Replimune, Inc. | $1.5B | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3NCT06887348observationalEvaluate the long-term safety of patients treated with an RPx product | — | Recruiting | Other: Observational study with no interventions | Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma | 50 | 2025-12-12 | Dec 2030 | ≤ 1,594 d | 2026-01-12 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsNCT04567615results2024-10-08Objective Response Rate(ORR) Assessed by BICR | Phase 2 | Completed | Biological: Nivolumab, Relatlimab | Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult | 266 | 2021-02-04 | 2023-08-31actual | — | 2026-01-08 |
| BMY | Bristol-Myers Squibb | $134.9B | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerNCT01658878results2025-12-24Number of Participants With Adverse Events (AEs) | Phase 1/2 | Completed | Biological: Nivolumab · Drug: Sorafenib, Ipilimumab, Cabozantinib | Hepatocellular Carcinoma | 657 | 2012-10-30 | 2024-11-12actual | — | 2025-12-24 |
| PII | Polaris Group | $3.8B | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaNCT05317819Overall Survival (OS) | Phase 3 | Recruiting | Drug: ADI-PEG20 · Other: Placebo | Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma | 300 | 2022-03-14 | Sep 2028 | ≤ 772 d | 2025-12-18 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791results2025-12-11Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population | Phase 3 | Active, not recruiting | Drug: Cabozantinib, Cabozantinib, Sorafenib, Atezolizumab | Hepatocellular Carcinoma | 837 | 2018-06-10 | 2021-11-30actual | — | 2025-12-11 |
| AZN | AstraZeneca | — | Imjudo & Imfinzi PMSNCT06544629observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs) | — | Recruiting | — | Hepatocellular Carcinoma | 246 | 2025-04-14 | 2029-02-28 | in 923 d | 2025-11-21 |
| 4523.T | Eisai Inc. | $8.7B | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsNCT05091346results2025-10-24Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs) | Phase 1/2 | Completed | Drug: E7386, Pembrolizumab, Lenvatinib | Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms | 89 | 2021-10-27 | 2024-10-15actual | — | 2025-10-24 |
| TLSI | TriSalus Life Sciences, Inc. | $333M | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsNCT05220722Phase 1b: To Determine the Safety of SD-101 Alone, in Combination with Pembrolizumab, and in Combination with Nivolumab and Ipilimumab | Phase 1/2 | Terminatedsponsor's stated reason: The decision was made to terminate the study after the completion of Phase 1b enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns. | Drug: SD-101 · Biological: Pembrolizumab, Nivolumab, Ipilimumab | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 23 | 2022-03-02 | 2024-07-31actual | — | 2025-10-23 |
| INCY | Incyte Corporation | $24.7B | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesNCT03144661Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB062079 | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors | 25 | 2017-05-25 | 2020-06-10actual | — | 2025-10-21 |
| MGNX | MacroGenics | $261M | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496Number of participants with adverse events (AEs) | Phase 1 | Completed | Biological: vobramitamab duocarmazine, lorigerlimab | Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma | 31 | 2022-04-19 | 2025-06-24actual | — | 2025-10-14 |
| ANGO | Angiodynamics, Inc. | $654M | International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRENCT07191548Target Tumour Eradication | Not applicable | Not yet recruiting | Device: Irreversible Electroporation | Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation, Liver Cancer, Adult | 50 | Feb 2026 | Feb 2028 | ≤ 558 d | 2025-10-10 |
| ANGO | Angiodynamics, Inc. | $654M | International Study on Treatment of Liver (HCC) Patients With IRENCT07192731Target Tumour Eradication | Not applicable | Not yet recruiting | Device: Irreversible Electroporation | Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult | 50 | Feb 2026 | Feb 2028 | ≤ 558 d | 2025-10-10 |
| AZN | AstraZeneca | — | Brazilian Reality of Hepatocellular CarcinomaNCT06230328observationalEpidemiological profile and pathological staging | — | Completed | — | Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage, Hepatocellular Carcinoma Stage I, Hepatocellular Carcinoma Stage II, Hepatocellular Carcinoma Stage III | 300 | 2024-04-15 | 2024-11-14actual | — | 2025-09-29 |
| SNY | Sanofi | — | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)NCT05104567results2025-07-01Cohort A: Objective Response Rate (ORR) | Phase 2 | Completed | Drug: THOR-707, Pembrolizumab, Cetuximab | Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma | 138 | 2021-12-09 | 2023-07-26actual | — | 2025-09-24 |
| TPST | Tempest Therapeutics | $16M | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258Overall Survival (OS) | Phase 3 | Not yet recruiting | Drug: TPST-1120 · Biological: Atezolizumab, Bevacizumab | Hepatocellular Carcinoma (HCC) | 740 | Dec 2025 | Dec 2028 | ≤ 864 d | 2025-09-03 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)NCT06109272Stage 1: Best Overall Response (BOR) per Investigator | Phase 2/3 | Recruiting | Drug: Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab | Hepatocellular Carcinoma | 660 | 2024-01-11 | Sep 2030 | ≤ 1,502 d | 2025-08-15 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)NCT05822752Best Overall Response (BOR) per Investigator | Phase 2 | Active, not recruiting | Drug: Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib | Hepatocellular Carcinoma | 130 | 2023-09-21 | Nov 2026 | ≤ 102 d | 2025-08-14 |
| BSX | Boston Scientific Corporation | $73.1B | Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)NCT04069468observationalOverall Survival (OS) | — | Completed | Device: TheraSphere | Hepatocellular Carcinoma | 1,247 | 2019-03-13 | 2024-12-31actual | — | 2025-07-23 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCB099280 | Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma | 182 | 2020-09-04 | 2024-08-29actual | — | 2025-07-14 |
| INCY | Incyte Corporation | $24.7B | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNCT04580485Number of treatment-emergent adverse events (TEAE) | Phase 1 | Completed | Drug: INCB106385, INCMGA00012 | Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal | 54 | 2021-02-03 | 2024-01-22actual | — | 2025-07-11 |
| AZN | AstraZeneca | — | LTFU for All Cell and Gene Therapy StudiesNCT06194461observationalIncidence of specific AEs | — | Not yet recruiting | Biological: AZD5851, AZD0754 | Hepatocellular Carcinoma, Prostate Cancer | 64 | 2025-09-17 | 2041-11-29 | in 5,580 d | 2025-06-27 |
| CHRS | Coherus Oncology, Inc. | $207M | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid TumorsNCT05757492Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab | Phase 1 | Terminatedsponsor's stated reason: The study was terminated for strategic reasons (not for safety concerns) | Drug: CHS-006 (anti-TIGIT), toripalimab (anti-PD-1) | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | 22 | 2023-04-26 | 2024-07-31actual | — | 2025-05-01 |
| CANF | Can-Fite BioPharma | — | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisNCT05201404Overall Survival (OS) | Phase 3 | Recruiting | Drug: Namodenoson, Placebo | Hepatocellular Carcinoma, Cirrhosis | 471 | 2023-03-15 | Feb 2026 | — | 2025-04-29 |
| TVRD | Tvardi Therapeutics, Incorporated | $25M | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced CancersNCT03195699Maximum Tolerated Dose of TTI-101 | Phase 1 | Completed | Drug: TTI-101, TTI-101 | Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer | 64 | 2017-11-15 | 2024-06-24actual | — | 2025-03-21 |
| INCY | Incyte Corporation | $24.7B | Study of INCB086550 in Select Solid TumorsNCT04629339results2025-03-13Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile. | Drug: INCB086550 | Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Melanoma | 16 | 2021-09-02 | 2024-03-26actual | — | 2025-03-13 |
| BSX | Boston Scientific Corporation | $73.1B | TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.NCT05233098results2025-03-06observationalDelivered Activity of Tc-99m MAA (MBq) for Whole Body | — | Completed | Device: Technetium-99m macroaggregated albumin (Tc-99m MAA) | Hepatocellular Carcinoma | 6 | 2022-04-04 | 2023-06-14actual | — | 2025-03-06 |
| INTS | Intensity Therapeutics, Inc. | $14M | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6NCT03058289results2024-08-13Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5) | Phase 1/2 | Completed | Drug: INT230-6 · Biological: anti-PD-1 antibody, anti-CTLA-4 antibody | Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma | 111 | 2017-02-09 | 2023-02-22actual | — | 2025-02-27 |
| INCY | Incyte Corporation | $24.7B | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsNCT05909995Occurence of DLTs | Phase 1 | Terminatedsponsor's stated reason: This was a strategic business decision. There were no safety concerns contributing to this decision. | Drug: INCB 99280 with Ipilimumab | Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC) | 8 | 2023-08-29 | 2024-09-19actual | — | 2025-02-18 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaNCT02576509results2020-06-26Overall Survival (OS) | Phase 3 | Completed | Drug: Nivolumab, Sorafenib | Hepatocellular Carcinoma | 743 | 2015-12-07 | 2019-05-30actual | — | 2025-02-17 |
| NVCR | NovoCure Ltd. | $2.0B | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)NCT03606590Overall response rate | Phase 2 | Completed | Device: NovoTTF-100L(P) device · Drug: Sorafenib | Hepatocellular Carcinoma | 25 | 2019-02-15 | 2021-01-14actual | — | 2024-11-14 |
| 4519.T | Chugai Pharmaceutical | $72.4B | A Phase I Study of ERY974 in Patients With Hepatocellular CarcinomaNCT05022927Safety and tolerability of ERY974 in combination with atezolizumab and bevacizumab (Dose limiting toxicities) [Dose escalation part] | Phase 1 | Active, not recruiting | Drug: ERY974, Tocilicumab, Atezolizumab, Bevacizumab | Hepatocellular Carcinoma (HCC) | 179 | 2021-06-01 | 2025-12-31 | — | 2024-09-05 |
| IMNN | Imunon | $9M | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)NCT02112656results2024-08-20Overall Survival (OS) | Phase 3 | Completed | Drug: ThermoDox, Dummy infusion | Hepatocellular Carcinoma | 554 | Jun 2014 | 2020-04-27actual | — | 2024-08-20 |
| AMGN | Amgen | $229.9B | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611NCT02509507results2022-12-30Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) | Phase 1/2 | Completed | Drug: Talimogene Laherparepvec, Pembrolizumab | Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors | 127 | 2016-02-05 | 2022-02-14actual | — | 2024-08-06 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular CarcinomaNCT04763408observationalNumber of Participants With Hepatotoxicity Treatment-emergent Adverse Events (TEAEs) With Lenvatinib | — | Completed | Drug: Lenvatinib, Sorafenib | Carcinoma, Hepatocellular | 335 | 2021-04-09 | 2023-12-13actual | — | 2024-07-18 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaNCT03418922results2024-06-20Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Lenvatinib, Nivolumab | Carcinoma, Hepatocellular | 30 | 2018-01-16 | 2022-12-28actual | — | 2024-06-20 |
| IPN.PA | Ipsen | $15.5B | Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsNCT03776123observationalNumber of patients experiencing Adverse Events (AEs)/ Serious Adverse Events (SAEs) after Cabometyx™ administration | — | Completed | — | Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma | 347 | 2019-05-15 | 2024-03-26actual | — | 2024-05-29 |
| IMNN | Imunon | $9M | Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)NCT00617981results2017-03-24Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause | Phase 3 | Completed | Drug: ThermoDox, 5% Dextrose Solution | Hepatocellular Carcinoma | 701 | May 2008 | Jan 2013actual | — | 2024-05-03 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsNCT02705105results2020-06-04Maximum Tolerated Dose (MTD) | Phase 1/2 | Completed | Biological: Mogamulizumab + Nivolumab | Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma, HCC | 114 | Feb 2016 | 2018-08-22actual | — | 2024-04-25 |
| PFE | Pfizer | $155.3B | Study of PF-07263689 in Participants With Selected Advanced Solid TumorsNCT05061537results2024-04-12Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study. | Biological: PF-07263689, Sasanlimab | Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma | 13 | 2021-10-20 | 2022-10-14actual | — | 2024-04-12 |
| AZN | AstraZeneca | — | OREIOS International StudyNCT05239507observationalTo describe the OS rate in patients with unresectable HCC including estimates of survival rates at 6, 12, and 18 months and at 2 years | — | Completed | — | Hepatocellular Carcinoma | 1,127 | 2022-02-01 | 2023-03-12actual | — | 2024-03-13 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaNCT03006926results2020-12-31DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Completed | Drug: lenvatinib, pembrolizumab (200 mg) | Hepatocellular Carcinoma | 104 | 2017-02-13 | 2019-10-31actual | — | 2023-12-13 |
| BMY | Bristol-Myers Squibb | $134.9B | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerNCT00355238results2023-12-01Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A | Phase 2 | Completed | Drug: brivanib (active) | Hepatocellular Carcinoma (HCC) | 137 | 2006-12-31 | 2010-04-30actual | — | 2023-12-01 |
| BSX | Boston Scientific Corporation | $73.1B | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerNCT01556490results2023-11-08Overall Survival (OS) Results Are Based on the Modified Intent-to-treat (mITT) | Not applicable | Completed | Device: TheraSphere | Unresectable Hepatocellular Carcinoma | 526 | Mar 2012 | 2022-04-30actual | — | 2023-11-08 |
| FATE | Fate Therapeutics | $307M | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNCT04106167observationalOverall Survival (OS) post-Infusion | — | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Genetic: Allogeneic natural killer (NK) cell | Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 20 | 2019-06-11 | 2023-08-11actual | — | 2023-09-21 |
| TPST | Tempest Therapeutics | $16M | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersNCT03829436Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab. | Phase 1 | Completed | Drug: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab | Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma | 38 | 2019-03-20 | 2022-09-07actual | — | 2023-07-03 |
| FATE | Fate Therapeutics | $307M | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsNCT03841110The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort. | Phase 1 | Completed | Drug: FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2 | Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 37 | 2019-02-15 | 2022-11-15actual | — | 2023-05-01 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-FetoproteinNCT02435433results2019-05-17Overall Survival (OS) | Phase 3 | Completed | Drug: Ramucirumab, Placebo | Hepatocellular Carcinoma | 399 | 2015-07-20 | 2018-03-15actual | — | 2023-01-20 |
| AZN | AstraZeneca | — | Himalaya Early Access ProgramNCT05345678expanded access | — | Approved for marketing | Drug: Durvalumab, Tremelimumab | Unresectable Hepatocellular Carcinoma | — | — | — | — | 2022-12-14 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488Determine the safety and tolerability profile of XmAb20717 | Phase 1 | Completed | Biological: XmAb20717 | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma | 150 | 2018-07-10 | 2022-06-01actual | — | 2022-12-01 |
| PVCT | Provectus Biopharmaceuticals, Inc. | $24M | A Study to Assess PV-10 Chemoablation of Cancer of the LiverNCT00986661Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of hepatic administration of PV-10 | Phase 1 | Unknown status | Drug: PV-10 (10% rose bengal disodium) | Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer | 78 | Oct 2009 | Dec 2022 | — | 2022-11-02 |
| DCTH | Delcath Systems Inc. | $585M | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaNCT02415036Objective response rate in percentage of Melphalan/HDS treatment | Phase 2 | Terminatedsponsor's stated reason: Limited enrollment | Device: Delcath Hepatic Delivery System · Drug: Melphalan | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 17 | Jun 2014 | Oct 2018actual | — | 2022-10-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Hepatocellular Carcinoma is matched — 12 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Hepatocellular Carcinoma
- Carcinoma, Hepatocellular
- Hepatocellular Carcinoma (HCC)
- Liver Cancer
- Advanced Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma
- Hepatocellular Cancer
- Liver Cancer, Adult
- Metastatic Hepatocellular Carcinoma
- Hepatocellular Carcinoma Recurrent
- Inoperable Hepatocellular Carcinoma
- Metastatic Liver Cancer
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Hepatocellular Carcinoma” (a text search, wider than this page)